The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Preliminary results from trials targeting mutant CALR for the treatment of MPNs
Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, comments on trials investigating agents that target mutant calreticulin (CALR) for the treatment of myeloproliferative neoplasms (MPNs). Prof. Kiladjian reports promising preliminary results, highlighting the potential of these therapies to alter the natural history of the disease. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Targeting mutant CALR with antibodies, is really something we wanted to see for many years. And hopefully we have now at least two clinical studies that have started for a while. Dose escalation studies, one of them, the first results will be presented for the first time during this meeting at EHA, concerning an antibody which is a neutral antibody that targets mutant CALR developed by the Insight company...
Targeting mutant CALR with antibodies, is really something we wanted to see for many years. And hopefully we have now at least two clinical studies that have started for a while. Dose escalation studies, one of them, the first results will be presented for the first time during this meeting at EHA, concerning an antibody which is a neutral antibody that targets mutant CALR developed by the Insight company. And we will show the results on the mutant CALR allele burden over time. So these are the first preliminary results showing really spectacular molecular responses with a huge decrease in the mutant CALR allele burden on treatment with this antibody. There’s another trial with a bispecific antibody, which is a different strategy, but both are addressing the same question of trying to get rid of the mutant cells and hopefully change the natural history of the disease. So preliminary results, but very encouraging data on molecular responses, at least with the first of these antibodies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
